News
TuHURA Biosciences
HURA · NASDAQ
$1.76−$0.02 (−1.12%)TodayMarket closed ·
Prev close $1.78
Latest news
- Press releasePRNewswire
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
- Press releasePRNewswire
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
- Press releasePRNewswire
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
- Press releasePRNewswire
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
- Press releasePRNewswire
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
- Press releasePRNewswire
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
- Press releasePRNewswire
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
- Press releasePRNewswire
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
- Press releasePRNewswire
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
- Press releasePRNewswire
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Press releasePRNewswire
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
- Press releasePRNewswire
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
- Press releasePRNewswire
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releasePRNewswire
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
- Press releasePRNewswire
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
- Press releasePRNewswire
TuHURA Biosciences Provides Corporate Update Following Recent Financing
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- Press releasePRNewswire
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
- Press releasePRNewswire
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
- Press releasePRNewswire
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- Press releasePRNewswire
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
- Press releasePRNewswire
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.